Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E28.31 EPS (ttm)1.19 Insider Own0.04% Shs Outstand6.01B Perf Week0.63%
Market Cap202.82B Forward P/E12.33 EPS next Y2.74 Insider Trans-6.67% Shs Float5.94B Perf Month5.07%
Income7.30B PEG5.02 EPS next Q0.66 Inst Own72.10% Short Float0.77% Perf Quarter-1.14%
Sales52.60B P/S3.86 EPS this Y5.20% Inst Trans-1.51% Short Ratio2.12 Perf Half Y3.97%
Book/sh9.73 P/B3.47 EPS next Y7.24% ROA4.20% Target Price37.35 Perf Year-0.09%
Cash/sh2.42 P/C13.93 EPS next 5Y5.64% ROE12.00% 52W Range29.83 - 37.39 Perf YTD3.97%
Dividend1.28 P/FCF30.18 EPS past 5Y3.30% ROI7.80% 52W High-9.68% Beta0.99
Dividend %3.79% Quick Ratio1.10 Sales past 5Y-2.80% Gross Margin77.30% 52W Low13.21% ATR0.40
Employees96500 Current Ratio1.40 Sales Q/Q-1.70% Oper. Margin18.00% RSI (14)60.65 Volatility1.15% 1.32%
OptionableYes Debt/Eq0.75 EPS Q/Q5.00% Profit Margin13.90% Rel Volume0.71 Prev Close34.04
ShortableYes LT Debt/Eq0.62 EarningsAug 01 BMO Payout100.70% Avg Volume21.54M Price33.77
Recom2.50 SMA202.70% SMA502.18% SMA2002.48% Volume15,215,662 Change-0.79%
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jun-27-17 04:03PM  [$$] Merck Cholesterol Drug Could Help Unlock Value
10:36AM  A Look at Pfizers Revenue for 1Q17 Market Realist
09:07AM  Pfizers Valuation as of June 22, 2017 Market Realist
09:03AM  Shocker: Merck Cholesterol Drug Yields Benefit Where Rivals Failed Forbes
09:00AM  Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri Business Wire
08:38AM  The Forgotten $35 Billion U.S. Healthcare Problem Forbes
08:08AM  2 Pharma Buyout Targets That May Surprise You Motley Fool
08:01AM  Pfizer Fueling Growth Of Competitors' Pipelines Forbes
07:38AM  Tanezumab Receives FDA Fast Track Designation Market Realist
Jun-26-17 09:30PM  15 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer
04:26PM  How Things Look for Opko Health, Inc. in 3 Charts Motley Fool
12:05PM  Pfizer Has Received Commercial Rights for Cresemba in Europe Market Realist
10:50AM  Pfizer Stock Looks Pretty Bullish for the Long Term Investopedia
10:38AM  Pfizers Xeljanz: Results from the ORAL Strategy Market Realist
10:24AM  After health care gains eight percent in one quarter CNBC Videos
08:40AM  Pfizers Progress on Its Group B Streptococcus Vaccine Market Realist
07:18AM  Trader shares top health-care play CNBC Videos
Jun-25-17 09:32AM  How To Find Dividend Payers With 100%+ Upside To Boot Forbes
06:48AM  3 Stocks to Help You Build Retirement Wealth Motley Fool
Jun-24-17 08:03AM  Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest Motley Fool
Jun-23-17 12:59PM  Greenwich Capital Commercial Funding Corp., 2005-GG3 -- Moody's Affirms Four Classes of GCCFC 2005-GG3 Moody's
10:28AM  Healthcare Stocks Make a Dumb Move on Trumpcare InvestorPlace
10:08AM  Biotech Movers: Regeneron Slides Back After Big Gains
09:06AM  Vertex on the Street: Analysts Recommendations in June 2017 Market Realist
05:10AM  Novartis breast cancer drug Kisqali wins European panel nod Reuters
Jun-22-17 05:05PM  Pfizer Inc. Value Analysis (NYSE:PFE) : June 22, 2017 Capital Cube
04:05PM  Pfizer Declares 32-Cent Third-Quarter 2017 Dividend Business Wire
12:33PM  Here's Why Sangamo Therapeutics Rose as Much as 11.7% Today Motley Fool
12:04PM  3 Big Stock Charts for Thursday: Pfizer Inc. (PFE), Wal-Mart Stores Inc (WMT) and Costco Wholesale Corporation (COST) InvestorPlace
11:27AM  10 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer
Jun-21-17 02:29PM  Will Pfizer Reexamine a Sale of its Consumer Division?
01:50PM  Dems Roast Trump for Leaving Medicare Out of Drug Price Order
01:08PM  Pfizer: Time to Sell the Consumer Biz?
12:22PM  Pfizer Firing on All Cylinders
10:00AM  S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017 PR Newswire
08:54AM  3 Stocks to Watch on Wednesday: Carmax, Inc (KMX), Adobe Systems Incorporated (ADBE) and Sangamo Therapeutics Inc (SGMO) InvestorPlace
Jun-20-17 01:35PM  Is Ford Motor Company (F) Stock Undervalued, Or Cheap for a Reason? InvestorPlace
01:26PM  Today's iQ100 leaders CNBC Videos
10:00AM  Pfizer Invites Public To View And Listen To Webcast Of August 1 Conference Call With Analysts Business Wire
09:55AM  Worldwide drug sale forecasts fall as pricing pressures mount Reuters
09:30AM  The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup Zacks
08:28AM  Pfizer Inc. breached its 50 day moving average in a Bullish Manner : PFE-US : June 20, 2017 Capital Cube
07:36AM  Regenerons Praluent May See Gradual Increase in 2017 Demand Market Realist
07:11AM  Better Buy: Pfizer Inc. vs. AbbVie Inc. Motley Fool
06:00AM  Top 10 Holdings of Our Ultimate Stock-Pickers' Index Morningstar
12:36AM  Can AstraZeneca Thrive on Its Own? Big Test Looms The Wall Street Journal
Jun-19-17 05:21PM  Why Exelixis, Inc. Zoomed Higher Today Motley Fool
05:06PM  Top Stock Reports for Chevron, Pfizer & Boeing Zacks
02:18PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
10:37AM  FDA Grants Fast-Track Designation to Tanezumab Market Realist
09:08AM  Eylea Continues to Be a Key Growth Driver for Regeneron in 2017 Market Realist
08:53AM  3 Biotech Stocks That More than Doubled Year to Date Zacks
08:00AM  [$$] Can AstraZeneca Thrive on Its Own? Big Test Looms The Wall Street Journal
08:00AM  Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine Business Wire
Jun-18-17 02:03PM  Could Legalized Marijuana Be Making Big Pharma Nervous? Motley Fool
Jun-17-17 11:42AM  3 Dividend Stocks for Successful Investors Motley Fool
Jun-16-17 04:41PM  Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs? Investor's Business Daily
08:27AM  Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused Zacks
07:37AM  5 best bets in biotech: Expert CNBC Videos
04:35AM  Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress Business Wire
Jun-15-17 01:08PM  [$$] European takeover rules merit a sceptical response Financial Times
12:15PM  Mylan In FDA Limbo On Generic Multiple Sclerosis Drug Investor's Business Daily
10:43AM  3 Stocks With Better Dividends Than CVS Health Corporation Motley Fool
09:40AM  Dont Be Scared of Biogen Inc (BIIB) Stock InvestorPlace
09:08AM  Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug Zacks
Jun-14-17 04:43PM  Johnson & Johnson: The Bear Case From a Bull Motley Fool
01:20PM  Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients Business Wire
01:16PM  Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel GlobeNewswire
10:57AM  Pfizer & Lilly Get Fast Track Designation for Pain Candidate Zacks
10:28AM  Company News for June 14, 2017 Zacks
09:59AM  Pfizer denies over-charging for cancer drugs in South Africa Reuters
Jun-13-17 05:07PM  Will Tesaro Be the Focus of the Next Biotech Bidding War? Motley Fool
12:27PM  Pfizer, Roche and Aspen face South African probe into cancer drug prices Reuters
12:16PM  Pfizer, Eli Lilly Granted Accelerated Review for Non-Opiod Pain Relief Drug
11:06AM  General Electric Company (GE) Stock: Immelts Departure Is Just the Start InvestorPlace
09:18AM  Merck: A Speed Bump For Keytruda?
09:00AM  Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey Business Wire
08:53AM  Eli Lilly stock rises 1.5% after pain drug gets fast track designation from FDA MarketWatch
08:06AM  Former Pfizer Scientist Is Resurrecting Projects To Solve The Multidrug Resistant Bacteria Problem Forbes
08:00AM  Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab Business Wire
06:00AM  Apple and Pfizer's Tax Windfall Investopedia
Jun-12-17 02:21PM  The Winners of Trump's Offshore Tax Plan Bloomberg Video
08:43AM  Merck's Diabetes Drug Meets Primary Endpoint in Key Studies Zacks
04:00AM  Trump's Offshore Tax Plan May Mean Extra Perk for Apple, Pfizer Bloomberg
12:50AM  [$$] U.S. Probe Sheds Light on Charities Role in Boosting Drug Sales The Wall Street Journal
Jun-11-17 09:24PM  [$$] U.S. Probe Sheds Light on Charities' Role in Boosting Drug Sales The Wall Street Journal
Jun-10-17 01:00PM  Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies Business Wire
Jun-09-17 04:45PM  Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma Motley Fool
03:32PM  Prostate Cancer Drug Sales Drop as Feds Investigate Charities
08:40AM  Opioids are ravaging the U.S., but theyre still the best pain drug weve got MarketWatch
08:00AM  Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer Business Wire
Jun-08-17 10:36AM  Why Pfizers Products Lost Market Share in 1Q17 Market Realist
09:12AM  Better Buy: Pfizer Inc. vs. Johnson & Johnson Motley Fool
09:06AM  What Drove Pfizer in 1Q17? Market Realist
07:46AM  Johnson & Johnsons new prostate cancer advances could signal trouble for Pfizer MarketWatch
07:36AM  Understanding Pfizers 1Q17 Performance by Geography Market Realist
Jun-07-17 05:35PM  Behind Pfizers Business Segments in 1Q17 Market Realist
04:25PM  Dow's Pfizer Faces Challenges As Roche, J&J, Lilly Loom Investor's Business Daily
04:05PM  Inside Pfizers 1Q17 Revenues Market Realist
02:22PM  What Happened to Pfizers Valuation after 1Q17? Market Realist
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It also has a research collaboration and license agreement with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads to be used in drug development; and an agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues for predicting drug induced liver injury. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON RADY AExecutive Vice PresidentMar 10Sale34.194,500153,85554,963Mar 13 05:36 PM
HILL CHARLES HExecutive Vice PresidentMar 09Sale34.0736,0001,226,52057,329Mar 10 03:59 PM
Dolsten MikaelPresident R&DMar 02Sale34.5515,401532,10549,318Mar 03 04:06 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 02Sale34.6620,000693,20083,793Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 01Sale34.4815,569536,81964,719Mar 03 04:06 PM
Dolsten MikaelPresident R&DFeb 27Sale34.2658,8462,016,24480,288Mar 01 05:10 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63572,172Feb 27 06:30 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.03103,1552,169,350295,356Feb 27 06:30 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0351,5781,084,685138,758Feb 27 06:30 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63533,848Feb 27 06:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03218,4474,593,940592,765Feb 27 06:21 PM
BOURLA ALBERTGroup PresidentFeb 23Option Exercise21.0342,476893,270165,474Feb 27 06:21 PM
Dolsten MikaelPresident R&DFeb 23Option Exercise21.03218,4474,593,940299,915Feb 27 06:21 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0336,408765,660102,611Feb 27 06:10 PM
READ IAN CChairman & CEOFeb 23Option Exercise21.03788,83516,589,2001,124,093Feb 27 06:55 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.03115,2912,424,570247,765Feb 27 06:55 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0351,5781,084,685172,542Feb 27 06:56 PM
OLSON LAURIE JExecutive Vice PresidentFeb 23Option Exercise21.0327,306574,24599,224Feb 27 06:47 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM